Itolizumab was very safe and did not seem to exacerbate opportunistic secondary infections. Unfortunately, we did no measure neither the frequency nor the total amount of circulating T cells in these initial patients. The impact of itolizumab on circulating T cells are being implementing in new recruited patients.